Searching for smart, safe news you can TRUST?
Support safe, smart, REAL journalism. Sign up for our Axios AM & PM newsletters and get smarter, faster.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Richard Drew / AP
Beleaguered drug company Valeant Pharmaceuticals has agreed to sell one of its subsidiaries, iNova Pharmaceuticals, to private-equity firms Pacific Equity Partners and The Carlyle Group for $930 million. The Australian-based iNova makes a slew of over-the-counter and prescription drugs.
Between the lines: Valeant is slimming down its drug operations, and this sale represents another attempt by CEO Joseph Papa to reduce the company's huge debt burden, which ballooned after the company acquired many other drug makers and controversially raised prices under ousted CEO Michael Pearson.